@Hip,
@leokitten,
Thank you for letting me know about the studies on pentoxifylline as an anticancerous agent. I have done a further reading of the available literature on the subject, and indeed, there are many papers showing an antineoplasic effects of pentoxyfilline in different cancers in mice.
While this is encouraging, I must add that the opposite seems to be also true: pentoxifilline can promote cancer growth in mice. For example, pentoxifylline promotes colon adenocarcinoma-derived metastatic tumor growth in lungs and also in liver of mice:
https://www.spandidos-publications.com/10.3892/or.11.5.1121/abstract
https://pubmed.ncbi.nlm.nih.gov/14534700
Similarly, it strongly promoted rhabdomyosarcoma-derived tumor growth in mice:
https://pubmed.ncbi.nlm.nih.gov/7974171/
A possible explanation, beyond the suppression of cytotoxicity, can be that this drug increases blood flow in cancerous cells. Thus, a human study inserted a catheter in cancerous lymph nodes of 11 oncologic patients with different types of cancer (adenocarcinoma, squamous cell carcinoma, lymphoma, melanoma, and transitional cell carcinoma), and found that pentoxifilline actually increased the blood flux into the tumors, accounting for one of the reasons why it helps chemotherapy to work. However, enhancing blood circulation through the tumors is a way of "feeding" them:
https://www.sciencedirect.com/science/article/abs/pii/S0167814001004935
So, how is it possible to show one thing and the oposite at the same time? Well, it seems that pentoxyfilline has anticancerous properties, including antineolasic, antifibrotic, and antiinflammatory properties. It also works at a molecular level inducing cell apoptosis, and inhibiting adhesion molecules on cancerous cells.
But, as I reviewed above, it seems to lower NK (and probably CD8+) citotoxicity as well as other key aspects of a necessary cellular response against cancer. So, I guess that depending on the type of cancer, it's location, and host's immunity status, it will go one way or another (in this regard, the increased blood flow of pentoxifylline to tumors was shown to be dependent on the location of the tumor, in mice:
https://europepmc.org/article/pmc/pmc1968634).
However I'd like to make an important point: I am concerned about people with ME/CFS taking this drug. And, ME/CFS patients are already immune-suppressed, with a reduced Th1 and cellular innate (NK dependant) response. Obviously this could tip the balance towards unwanted side effects.
Also, many ME/CFS patients have tested positive for infections, including Lyme disease (I have, by CDC criteria, and meet ME/CFS diagnostic criteria as well).
So, do we know what might happen if we take pentoxifylline with a chronic infection? Well, here's a study showing that pentoxifilline worsens lung damage in mice with chronic tuberculosis:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783172/
In summary, I think I have reached a dead end regarding whether the use of pentoxifylline may be dangerous or not. We just do not have enough data, and prospective longitudinal trials in humans are needed.
I think I will err on the safe side though, and won't take this drug for now.
I'm sorry for the "assay"! I really appreciate your inputs and the debate!
Best,
Sergio